1. Signaling Pathways
  2. Anti-infection
  3. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N2116R
    Ginkgolic acid C17:1 (Standard)
    Inhibitor
    Ginkgolic acid C17:1 (Standard) is the analytical standard of Ginkgolic acid C17:1. This product is intended for research and analytical applications. Ginkgolic acid C17:1 is a fatty acid synthase (FAS) inhibitor with an IC50 of 10.5 µM. Ginkgolic acid C17:1 shows anti-tumor activity by inhibiting the phosphorylation of STAT3 and inducing apoptosis. Ginkgolic acid C17:1 can block the interaction between S-RBD and ACE2, and has anti-SARS-CoV-2-S pseudovirus activity. Ginkgolic acid C17:1 inhibits the biofilm formation of enterohemorrhagic Escherichia coli and Staphylococcus aureus.
    Ginkgolic acid C17:1 (Standard)
  • HY-162464
    MPD2
    Inhibitor
    MPD2 is a Cereblon-binding ligand-based PROTAC that degrades MPro, the main protease of SARS-CoV-2. MPD2 effectively reduced MPro protein levels in 293T cells in a time-dependent manner (DC50=296 nM). MPD2 exhibited potent antiviral activity against multiple SARS-CoV-2 strains and had enhanced potency against Nirmatrelvir (HY-138687) resistant strains. MPD2 provides a new direction for antiviral drug development against SARS-CoV-2 and other emerging coronavirus pathogens (Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker (HY-W275882);Red: SARS-CoV-2 MPro Inhibitor MP18 (HY-158763)).
    MPD2
  • HY-131603
    Lamivudine triphosphate
    Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA.
    Lamivudine triphosphate
  • HY-151502
    Antimicrobial agent-12
    Inhibitor
    Antimicrobial agent-12 is a potent antibacterial agent with SARS-CoV-2 inhibitory activity.
    Antimicrobial agent-12
  • HY-139732
    SARS-CoV-2-IN-8
    Inhibitor
    SARS-CoV-2-IN-8 is a SARS-CoV-2 main protease inhibitor with an IC50 value of 0.75 μM.
    SARS-CoV-2-IN-8
  • HY-151901
    SARS-CoV-2 Mpro-IN-5
    Inhibitor
    SARS-CoV-2 Mpro-IN-5 is a dual Inhibitor of Main Protease (MPro) and Cathepsin L (CatL), with IC50s of 1800 nM and 145 nM respectively. SARS-CoV-2 Mpro-IN-5 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-5 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 14.7 nM.
    SARS-CoV-2 Mpro-IN-5
  • HY-144120
    αGalCer-RBD
    Inhibitor
    αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist. RBD: receptor-binding domain
    αGalCer-RBD
  • HY-N0191S
    Andrographolide-d
    Andrographolide-d (Andrographis-d) is the deuterium labeled Andrographolide (HY-N0191). Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
    Andrographolide-d
  • HY-168259
    PLpro-IN-8
    Inhibitor
    PLpro-IN-8 (compound 1) is a SARS-CoV papain-like protease (PLpro) inhibitor with IC50 values of 5.9 μM and 0.46 μM for SARS-CoV-2 PLpro and SARS -CoV-1 PLpro, respectively. PLpro-IN-8 inhibits Wuhan strain WK-521 of SARS-CoV-2 with an EC50 of 2.7 μM.
    PLpro-IN-8
  • HY-180318
    MI-30
    Inhibitor
    MI-30 is an orally active SARS-CoV-2 3CLpro inhibitor (IC50 = 17.2 nM). MI-30 reduces viral load and lung lesions in a mouse model of SARS-CoV-2 infection. MI-30 may be used in coronavirus infection research.
    MI-30
  • HY-161791
    Mpro ligand 2
    Mpro ligand 2 (Compound 8) is the ligand for target protein, which can be used for synthesis of PROTAC SARS-CoV-2 Mpro degrader-3 (HY-161789).
    Mpro ligand 2
  • HY-147516
    SARS-CoV-2-IN-21
    Inhibitor
    SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent SARS-CoV-2 main protease inhibitor, with an IC50 of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research.
    SARS-CoV-2-IN-21
  • HY-155136
    NSC89641
    Inhibitor
    NSC89641 inhibits MERS-CoV Mpro, with an IC50 value < 3.5 μM. NSC89641 exhibits the high inhibitory potency against SARS-CoV-2 Mpro enzymatic activity, with an IC50 of 3.05 μM.
    NSC89641
  • HY-B0689B
    Indinavir sulfate ethanolate
    Inhibitor
    Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CLpro inhibitor.
    Indinavir sulfate ethanolate
  • HY-N10661
    Ipomoeassin F
    Inhibitor
    Ipomoeassin F is a potent and selective endoplasmic reticulum (ER) protein-translocation inhibitor by targeting the pore-forming subunit of the Sec61 complex (Sec61α) at the ER membrane. Ipomoeassin F selectively inhibits the ER membrane translocation of SARS-CoV-2 proteins. Ipomoeassin F block the ER translocation of secretory proteins and type I transmembrane proteins (TMPs), but not type III TMPs.
    Ipomoeassin F
  • HY-171781
    FL-166
    Inhibitor
    FL-166 is a SARS coronavirus main protease (Mpro) inhibitor (Ki: 40 nM). FL-166 exerts its inhibitory effect by targeting a cluster of serine residues near the active site of the protease. FL-166 can be used in the study of SARS-CoV.
    FL-166
  • HY-151900
    SARS-CoV-2 Mpro-IN-4
    Inhibitor
    SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of Main Protease (MPro) and Cathepsin L (CatL), with IC50s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 8.2 nM.
    SARS-CoV-2 Mpro-IN-4
  • HY-B0462S
    Azelastine-13C,d3 hydrochloride
    Inhibitor
    Azelastine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled Azelastine hydrochloride. Azelastine-13C,d3 (hydrochloride), an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine-13C,d3 (hydrochloride) can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
    Azelastine-<sup>13</sup>C,d<sub>3</sub> hydrochloride
  • HY-152108
    SARS-CoV-2 Mpro-IN-6
    Inhibitor
    SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective SARS-CoV-2 Mpro inhibitor with an IC50 of 0.18 μM. SARS-CoV-2 Mpro-IN-6 does not inhibit human cathepsins B, F, K, and L, and caspase 3.
    SARS-CoV-2 Mpro-IN-6
  • HY-131262
    Hydroxychloroquine Impurity E
    99.83%
    Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro.
    Hydroxychloroquine Impurity E
Cat. No. Product Name / Synonyms Species Source